Notice of Proposed Sale · 144
SOPHiA GENETICS SA
SOPHNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- SOPHIA GENETICS SA
- Issuer CIK
- 0001840706
- SEC file number
- 001-40627
- Phone
- 41216941060
- Person for whose account securities are to be sold
- ROSS J MUKEN
- Relationships to issuer
- Officer
- Street
- La Piece 12 ch-1180
- City
- Rolle
- State / country code
- V8
- Postal code
- 00000
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 9,838 | 52,633.30 | 71,790,366 | 07/06/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/02/2026 | Restricted Stock Units | Issuer | 9,838 | N | 07/02/2026 | N/A |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| 10b5-1 Sales for ROSS J MUKEN | Common | 06/22/2026 | 422 | 2,270.49 |
| 10b5-1 Sales for ROSS J MUKEN | Common | 05/19/2026 | 761 | 3,501.06 |
| 10b5-1 Sales for ROSS J MUKEN | Common | 04/20/2026 | 760 | 3,954.96 |
| 10b5-1 Sales for ROSS J MUKEN | Common | 04/14/2026 | 2,800 | 13,887.16 |
| 10b5-1 Sales for ROSS J MUKEN | Common | 04/13/2026 | 4,442 | 21,166.13 |
| 10b5-1 Sales for ROSS J MUKEN | Common | 04/10/2026 | 3,687 | 17,278.76 |
| 10b5-1 Sales for ROSS J MUKEN | Common | 04/09/2026 | 1,950 | 9,238.91 |
| 10b5-1 Sales for ROSS J MUKEN | Common | 04/08/2026 | 2,786 | 13,488.14 |
| 10b5-1 Sales for ROSS J MUKEN | Common | 04/07/2026 | 2,424 | 11,801.49 |
Seller — prior-sale row 1, entry 1
- Name
- 10b5-1 Sales for ROSS J MUKEN
- Street
- La Piece 12 ch-1180
- City
- Rolle
- State / country code
- V8
- Postal code
- 00000
Seller — prior-sale row 2, entry 1
- Name
- 10b5-1 Sales for ROSS J MUKEN
- Street
- La Piece 12 ch-1180
- City
- Rolle
- State / country code
- V8
- Postal code
- 00000
Seller — prior-sale row 3, entry 1
- Name
- 10b5-1 Sales for ROSS J MUKEN
- Street
- La Piece 12 ch-1180
- City
- Rolle
- State / country code
- V8
- Postal code
- 00000
Seller — prior-sale row 4, entry 1
- Name
- 10b5-1 Sales for ROSS J MUKEN
- Street
- La Piece 12 ch-1180
- City
- Rolle
- State / country code
- V8
- Postal code
- 00000
Seller — prior-sale row 5, entry 1
- Name
- 10b5-1 Sales for ROSS J MUKEN
- Street
- La Piece 12 ch-1180
- City
- Rolle
- State / country code
- V8
- Postal code
- 00000
Seller — prior-sale row 6, entry 1
- Name
- 10b5-1 Sales for ROSS J MUKEN
- Street
- La Piece 12 ch-1180
- City
- Rolle
- State / country code
- V8
- Postal code
- 00000
Seller — prior-sale row 7, entry 1
- Name
- 10b5-1 Sales for ROSS J MUKEN
- Street
- La Piece 12 ch-1180
- City
- Rolle
- State / country code
- V8
- Postal code
- 00000
Seller — prior-sale row 8, entry 1
- Name
- 10b5-1 Sales for ROSS J MUKEN
- Street
- La Piece 12 ch-1180
- City
- Rolle
- State / country code
- V8
- Postal code
- 00000
Seller — prior-sale row 9, entry 1
- Name
- 10b5-1 Sales for ROSS J MUKEN
- Street
- La Piece 12 ch-1180
- City
- Rolle
- State / country code
- V8
- Postal code
- 00000
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
The securities to be sold were acquired upon the vesting of restricted stock units on 07/02/2026 and 07/03/2026.
Notice signature
- Notice date
- 07/06/2026
- Signed
- /s/ Ross J Muken
- Plan adoption dates
- 08/26/2025
Company context
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.